DK1637593T3 - Fremgangsmåde til inaktivering af lipidomhyllede vira - Google Patents

Fremgangsmåde til inaktivering af lipidomhyllede vira

Info

Publication number
DK1637593T3
DK1637593T3 DK05112299.2T DK05112299T DK1637593T3 DK 1637593 T3 DK1637593 T3 DK 1637593T3 DK 05112299 T DK05112299 T DK 05112299T DK 1637593 T3 DK1637593 T3 DK 1637593T3
Authority
DK
Denmark
Prior art keywords
viruses
intact
structural integrity
enveloped viruses
vaccine
Prior art date
Application number
DK05112299.2T
Other languages
English (en)
Inventor
Noel Barrett
Otfried Kistner
Friedrich Dorner
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of DK1637593T3 publication Critical patent/DK1637593T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation
    • C12N2710/16763—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24163—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DK05112299.2T 1997-02-24 1998-02-12 Fremgangsmåde til inaktivering af lipidomhyllede vira DK1637593T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0029997A AT405939B (de) 1997-02-24 1997-02-24 Verfahren zur inaktivierung von lipidumhüllten viren
EP98890036A EP0864646B1 (de) 1997-02-24 1998-02-12 Verfahren zur Inaktivierung von lipidumhüllten Viren

Publications (1)

Publication Number Publication Date
DK1637593T3 true DK1637593T3 (da) 2010-11-22

Family

ID=3486870

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05112299.2T DK1637593T3 (da) 1997-02-24 1998-02-12 Fremgangsmåde til inaktivering af lipidomhyllede vira
DK98890036T DK0864646T3 (da) 1997-02-24 1998-02-12 Fremgangsmåde til inaktivering af kappevira

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK98890036T DK0864646T3 (da) 1997-02-24 1998-02-12 Fremgangsmåde til inaktivering af kappevira

Country Status (7)

Country Link
US (1) US6136321A (da)
EP (2) EP1637593B1 (da)
JP (1) JPH10234362A (da)
AT (3) AT405939B (da)
DE (2) DE59813677D1 (da)
DK (2) DK1637593T3 (da)
ES (2) ES2270501T3 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2236378C (en) 1995-11-01 2011-01-25 Dnavec Research Inc. Recombinant sendai virus
JP4540795B2 (ja) * 2000-03-10 2010-09-08 一般財団法人阪大微生物病研究会 生ワクチンの細胞性免疫活性を不活化ワクチンにも起こさせる方法、及びこれより得られる混合ワクチン
US7407662B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified viral particles with immunogenic properties and reduced lipid content
AU2008201523B2 (en) * 2000-06-29 2011-07-28 Eli Lilly And Company Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
AU2004264842B2 (en) * 2000-06-29 2008-01-10 Eli Lilly And Company Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
US20090017069A1 (en) 2000-06-29 2009-01-15 Lipid Sciences, Inc. SARS Vaccine Compositions and Methods of Making and Using Them
US7407663B2 (en) * 2000-06-29 2008-08-05 Lipid Sciences, Inc. Modified immunodeficiency virus particles
AUPQ846900A0 (en) * 2000-06-29 2000-07-27 Aruba International Pty Ltd A vaccine
BR0114392A (pt) * 2000-10-02 2003-09-02 Glaxosmithkline Biolog Sa Formulação de vacina, método para produzir uma formulação de vacina, uso de uma preparação de vacina contra rsv dividido, kit para liberação de uma formulação de vacina intranasal, dispositivo de liberação intranasal, e, método para proteger ou tratar um mamìfero susceptìvel a, ou sofrendo de doença causada por rsv
DK1326963T3 (da) 2000-10-17 2008-08-25 Zeptometrix Corp Mikroorganismer, som er gjort ikke-patogene
US6524586B2 (en) 2001-05-18 2003-02-25 Albany Medical College Enhancement of oligomeric viral immunogenicity
WO2003000372A2 (en) * 2001-06-25 2003-01-03 Lipid Sciences, Inc. Systems and methods using multiple solvents for the removal of lipids from fluids
US6991727B2 (en) * 2001-06-25 2006-01-31 Lipid Sciences, Inc. Hollow fiber contactor systems for removal of lipids from fluids
US20030127386A1 (en) * 2001-06-25 2003-07-10 Bomberger David C. Hollow fiber contactor systems for removal of lipids from fluids
US7393826B2 (en) 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
CA2531227A1 (en) 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
US20090214590A1 (en) * 2005-07-08 2009-08-27 Wayne State University Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568210A (en) * 2005-11-04 2012-12-21 Novartis Vaccines & Diagnostic Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
HUE051122T2 (hu) 2005-11-04 2021-03-01 Seqirus Uk Ltd Sejttenyészetben növesztett influenzavírusból elõállított nemvirion anti-géneket tartalmazó adjuvált vakcinák
CN101790381B (zh) * 2007-08-28 2014-08-27 巴克斯特国际公司 生产病毒疫苗的方法
EP2396032B1 (en) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
US20110110975A1 (en) * 2009-11-06 2011-05-12 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
EP2704740B1 (en) 2011-05-04 2016-10-05 Streck, Inc. Inactivated swine flu virus and methods of preparing it
KR102238133B1 (ko) 2013-11-15 2021-04-09 제넨테크, 인크. 환경-친화적 세제를 사용한 바이러스 불활성화 방법
MX2020004543A (es) * 2017-11-03 2020-09-18 Takeda Vaccines Inc Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
WO2019104237A1 (en) 2017-11-22 2019-05-31 Hdl Therapeutics, Inc. Systems and methods for priming fluid circuits of a plasma processing system
MX2020004633A (es) * 2017-11-30 2020-09-28 Takeda Vaccines Inc Metodo para inactivar el virus de zika y metodos relacionados.
WO2019133358A2 (en) 2017-12-28 2019-07-04 Hdl Therapeutics, Inc. Methods for preserving and administering pre-beta high density lipoprotein extracted from human plasma
MX2022006987A (es) * 2019-12-12 2022-07-13 Lilly Co Eli Metodos para la inactivacion viral mediante detergentes compatibles con el medioambiente.
CN115996940A (zh) * 2020-07-01 2023-04-21 免疫医疗有限责任公司 用于纯化生物治疗剂的洗涤剂和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164565A (en) 1975-03-14 1979-08-14 New York Blood Center, Inc. Vaccine for active immunization containing hepatitis B surface antigen and associated antigen
DE3014189A1 (de) * 1980-04-14 1981-10-15 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren
US4314997A (en) 1980-10-06 1982-02-09 Edward Shanbrom Purification of plasma protein products
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
DE3704550A1 (de) * 1987-02-13 1988-08-25 Behringwerke Ag Verfahren zur inaktivierung huellhaltiger viren in mittels einer zelle in vitro hergestellten protein-praeparationen
CZ288048B6 (cs) * 1991-07-25 2001-04-11 Idec Pharmaceuticals Corporation Farmaceutická kompozice k indukci cytotoxické odpovědi T-lymfocytů
DE4211108A1 (de) * 1992-04-03 1993-10-07 Boehringer Mannheim Gmbh Viruslösung zum Einsatz bei Immunoassays
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines

Also Published As

Publication number Publication date
ATE478138T1 (de) 2010-09-15
EP1637593B1 (de) 2010-08-18
JPH10234362A (ja) 1998-09-08
AT405939B (de) 1999-12-27
DE59814464D1 (de) 2010-09-30
DE59813677D1 (de) 2006-09-21
ES2270501T3 (es) 2007-04-01
EP0864646B1 (de) 2006-08-09
US6136321A (en) 2000-10-24
ES2350109T3 (es) 2011-01-18
EP1637593A1 (de) 2006-03-22
EP0864646A3 (de) 2002-05-15
EP0864646A2 (de) 1998-09-16
DK0864646T3 (da) 2006-11-20
ATE335810T1 (de) 2006-09-15
ATA29997A (de) 1999-05-15

Similar Documents

Publication Publication Date Title
DK1637593T3 (da) Fremgangsmåde til inaktivering af lipidomhyllede vira
ES511668A0 (es) "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante".
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
ES2083353T3 (es) Sistema infectivo de liberacion de farmacos.
DK0588578T4 (da) Præparat, der indeholder både en oplöselig og en uoplöselig form af et immunogen
DK0931830T3 (da) Cytopatiske vira til terapi og profylakse af neoplasi
CO4810339A1 (es) Nuevas estructuras artificiales de proteinas de fusion y metodo de preparacion
DE59410380D1 (de) Endosomolytisch wirksame partikel
ES2191663T3 (es) Virus recombinante de la viruela porcina.
IE38825B1 (en) Stable viral preparations
BR9814204A (pt) "obtenção de vacinas destinadas a prevenir os efeitos patogênicos associados a uma infecção retroviral"
HUT42910A (en) Method for modifying vegetal viruses or their effect
ES2058418T3 (es) Preparacion farmaceutica contra enfermedades viricas que comprende un extracto de higado.
DK0512011T3 (da) Blodfaktorer fremstillet ved rekombinant DNA-teknologi, fremgangsmåde til ekspression af blodfaktorerne samt vacciniavirusrekombinanter anvendt ved fremgangsmåden
CA2153780A1 (en) Method of inhibiting viral reproduction
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
DK0480949T3 (da) Fremstilling af virus og oprensning af virale kappeproteiner til vaccineanvendelse
AR001399A1 (es) Una composición acondicionadora del cabello.
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
DK8789A (da) Fremgangsmaade til fremstilling af modificerede, staerkt afsvaekkede rna-virusstammer samt vaccine og dens anvendelse
PT88430A (pt) Vecteur d'expression des proteines du virus hiv-2 un agent causal du sida culture cellulaire infectee ou transformee par ce vecteur procede de preparation de proteines et d'un vaccin et anticorps obtenus
ES550089A0 (es) Procedimiento para producir una vacuna coadyuvada que contiene un antigeno seleccionado de proteinas, bacterias y virus.
WO2000061613A3 (en) Channel forming toxins as antiviral agents
FI893346A (fi) Icke-reverterande rna-virus.
DE69422980D1 (de) Extrakte von Piliostigma thonningii, deren Verwendung und diese enthaltende Zubereitungen